Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.03, $0.07 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.7 million versus the consensus estimate of $28.87 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.